Artelo Biosciences, INC 8-K filings

Artelo Biosciences has raised $900,000 by issuing convertible notes to investors, with potential conversion into common stock and warrants.

Artelo Biosciences received a notice from Nasdaq indicating non-compliance with the $1.00 minimum bid price requirement for continued listing.

Artelo Biosciences successfully held its annual meeting, re-electing two directors and ratifying its independent auditor for the fiscal year ending December 31, 2024.

Artelo Biosciences has repriced and revised the vesting schedule of certain stock options to retain and incentivize key employees and directors.